Danaher Unit Fights Amgen Subpoena in Fresenius Biosimilars Case

A Danaher Corp. unit urged a federal court to quash Amgen Inc.’s subpoena in a patent suit over Fresenius SE & Co.’s biosimilars of Prolia and Xgeva, arguing Amgen seeks confidential details about a cell-culture ingredient that would expose its trade secrets.

HyClone Laboratories, a Utah-based subsidiary of Danaher’s Cytiva, said Amgen hasn’t shown why its off-the-shelf Cell Boost 7a supplement or any of the 22 “overbroad categories of requested information, particularly those pertaining to the formulation and manufacturing of CB7A, are actually relevant to ...